Researchers at the RIKEN Center for Developmental Biology will treat the first patient in its clinical trial testing an induced pluripotent stem cell-based treatment for age-related macular degeneration.
The researcher who falsely claimed to treat human patients with their own stem cells is dismissed, but insists that he did perform the procedure on one patient.
Researchers employ peripheral blood mononuclear cells (PBMCs) in clinical and academic applications related to the immune system and regenerative medicine.